The Administration Core (Core A) will coordinate and support the programmatic, fiscal, oversight and developmental endeavors upon which the translational success of the SARC Sarcoma SPORE depends. The goals of the SPORE are to translate biological and technological advances into improvements in prevention, diagnostics, predictors of outcome, and particularly -advances in the treatment of sarcoma. The SARC Sarcoma SPORE is anchored by multiple researchers from SARC, Harvard, and MD Anderson Cancer Center, but also includes key individual researchers from Stanford University, Columbia University and The University of Michigan. The researchers represent medical and pediatric oncology and the projects explore both soft tissue and bone sarcomas. Four major projects are proposed: 1) Rational HDACi-based therapeutic strategies for the treatment of genetically complex STS;2) Developing effective combination therapies for malignant peripheral nerve sheath tumor (MPNST);3) Identification of biomarkers of response to G-protein coupled receptors and novei therapeutic targets in Ewing's sarcoma;and 4) Developing quantitative imaging biomarkers for assessing therapeutic response to sarcoma therapy. These projects are integrated and supported by 4 cores: 1) Administration, Evaluation and Planning;2) Tissue and Pathology; 3) Clinical Trials;and 4) Biostatistics. The SP0RE application outlines a Developmental Research Program that includes a plan for selection of new projects as well as 14 proposed developmental pilot projects. We also inciude a Career Development Program that outlines a mechanism for the identification and support of talented young investigators in translational or clinical sarcoma research. The projects and cores proposed in this application are highly integrated and are poised to take maximum advantage ofthe SPORE mechanism to achieve translational goals. This SPORE joins the foremost sarcoma investigators and state-of-the art research projects with the multi-institution, collaborative strength of SARC and commitments from leading institutions to produce successful translational advances in the diagnosis, treatment, and prevention of sarcoma.
The SPORE progrann will advance sarcoma therapeutics by combining and integrating nation-wide translational research strengths. Success in this endeavor will require capable and well-supported administrative center, which will maximize opportunities for existing projects and cores, coordinate oversight ofthe SPORE, and encourage career development and development of promising new project concepts.
|Nakayama, Robert; Zhang, Yi-Xiang; Czaplinski, Jeffrey T et al. (2016) Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget 7:16581-92|
|Goldstein, Seth D; Trucco, Matteo; Bautista Guzman, Wendy et al. (2016) A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model. Oncotarget 7:21114-23|
|Schaefer, Inga-Marie; Fletcher, Christopher Dm; Hornick, Jason L (2016) Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol 29:4-13|
|MariÃ±o-EnrÃquez, AdriÃ¡n; BovÃ©e, Judith V M G (2016) Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma. Surg Pathol Clin 9:457-73|
|Tang, Qin; Moore, John C; Ignatius, Myron S et al. (2016) Imaging tumour cell heterogeneity following cell transplantation into optically clear immune-deficient zebrafish. Nat Commun 7:10358|
|Bobowski, Nina P; Baker, Laurence H (2016) The University of Michigan Sarcoma Survivorship Clinic: Preventing, Diagnosing, and Treating Chronic Illness for Improved Survival and Long-Term Health. J Adolesc Young Adult Oncol 5:211-4|
|Koehler, K; Liebner, D; Chen, J L (2016) TP53 mutational status is predictive of pazopanib response in advanced sarcomas. Ann Oncol 27:539-43|
|Bid, Hemant K; Phelps, Doris A; Xaio, Linlin et al. (2016) The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Mol Cancer Ther 15:1018-28|
|Simon, Priscilla S; Bardhan, Kankana; Chen, May R et al. (2016) NF-ÎºB functions as a molecular link between tumor cells and Th1/Tc1 T cells in the tumor microenvironment to exert radiation-mediated tumor suppression. Oncotarget 7:23395-415|
|De Rienzo, Assunta; Archer, Michael A; Yeap, Beow Y et al. (2016) Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma. Cancer Res 76:319-28|
Showing the most recent 10 out of 86 publications